MXPA04004656A - Sintesis y purificacion de valaciclovir. - Google Patents

Sintesis y purificacion de valaciclovir.

Info

Publication number
MXPA04004656A
MXPA04004656A MXPA04004656A MXPA04004656A MXPA04004656A MX PA04004656 A MXPA04004656 A MX PA04004656A MX PA04004656 A MXPA04004656 A MX PA04004656A MX PA04004656 A MXPA04004656 A MX PA04004656A MX PA04004656 A MXPA04004656 A MX PA04004656A
Authority
MX
Mexico
Prior art keywords
valacyclovir
valine
protected
making
present
Prior art date
Application number
MXPA04004656A
Other languages
English (en)
Inventor
Zion Dolitzky Ben
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA04004656A publication Critical patent/MXPA04004656A/es
Publication of MX242714B publication Critical patent/MX242714B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se relaciona con valaciclovir protegido, ester de N-terc-butoxicarbonil-L-valina 2-[(2-amino-1, 6-dihidro-6-oxo-9H-purin-9-il)metoxil] etilo, y un metodo de fabricacion de el. La presente invencion ademas se relaciona con un metodo de fabricacion de valaciclovir que incluye los pasos de acoplar una valina protegida con amina que se selecciona de N-butoxicarbonil valina y N-formil valina con aciclovir utilizando un agente de acoplamiento para formar un valaciclovir protegido, y desproteger el valaciclovir protegido para formar valaciclovir o una sal farmaceuticamente aceptable de el. La presente invencion se relaciona ademas con valaciclovir en forma pura, con un metodo de fabricacion de valaciclovir puro, y con composiciones que contienen valciclovir puro.
MXPA04004656 2001-11-14 2002-11-13 Sintesis y purificacion de valaciclovir. MX242714B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33280201P 2001-11-14 2001-11-14
US34227301P 2001-12-21 2001-12-21
PCT/US2002/036269 WO2003041647A2 (en) 2001-11-14 2002-11-13 Synthesis and purification of valacyclovir

Publications (2)

Publication Number Publication Date
MXPA04004656A true MXPA04004656A (es) 2004-08-13
MX242714B MX242714B (es) 2006-12-15

Family

ID=26988392

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004656 MX242714B (es) 2001-11-14 2002-11-13 Sintesis y purificacion de valaciclovir.

Country Status (14)

Country Link
US (2) US6849737B2 (es)
EP (1) EP1465894A4 (es)
JP (1) JP2005508993A (es)
KR (2) KR20050044449A (es)
CN (1) CN1307177C (es)
CA (2) CA2649826A1 (es)
HR (1) HRP20040511A2 (es)
IL (1) IL161969A0 (es)
IN (1) IN2007DE04250A (es)
IS (1) IS7260A (es)
MX (1) MX242714B (es)
NO (1) NO20042433L (es)
PL (1) PL371732A1 (es)
WO (1) WO2003041647A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436295A4 (en) * 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) * 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
WO2006011874A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries, Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2578750A1 (en) 2004-09-04 2006-03-16 Teva Pharmaceutical Industries, Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US7958087B2 (en) * 2004-11-17 2011-06-07 Iron Mountain Incorporated Systems and methods for cross-system digital asset tag propagation
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
WO2008139539A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. バラシクロビルの製造方法
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
WO2017149420A1 (en) * 2016-03-03 2017-09-08 Aurobindo Pharma Ltd Process for the preparation of valacyclovir
CN106632335A (zh) * 2016-12-27 2017-05-10 河南康达制药有限公司 一种盐酸伐昔洛韦的制备方法
CN114621227B (zh) * 2022-02-28 2024-07-09 海南久常制药有限公司 一种盐酸伐昔洛韦、制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5672243A (en) * 1995-11-28 1997-09-30 Mosel Vitelic, Inc. Antireflection coating for highly reflective photolithographic layers comprising chromium oxide or chromium suboxide
DK0874631T3 (da) * 1996-01-19 2004-03-22 Glaxo Group Ltd Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998021223A1 (en) * 1996-11-12 1998-05-22 Medivir Ab Nucleosides
EP1436295A4 (en) * 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) * 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof

Also Published As

Publication number Publication date
CA2649826A1 (en) 2003-05-22
HRP20040511A2 (en) 2004-10-31
WO2003041647A3 (en) 2003-11-20
EP1465894A4 (en) 2008-10-08
PL371732A1 (en) 2005-06-27
IL161969A0 (en) 2005-11-20
CN1307177C (zh) 2007-03-28
CN1612878A (zh) 2005-05-04
NO20042433L (no) 2004-07-22
CA2465928A1 (en) 2003-05-22
EP1465894A2 (en) 2004-10-13
US6849737B2 (en) 2005-02-01
JP2005508993A (ja) 2005-04-07
US20050130993A1 (en) 2005-06-16
IS7260A (is) 2004-05-11
WO2003041647A2 (en) 2003-05-22
KR20070020149A (ko) 2007-02-16
IN2007DE04250A (es) 2007-08-31
KR20050044449A (ko) 2005-05-12
MX242714B (es) 2006-12-15
US20030153757A1 (en) 2003-08-14
CA2465928C (en) 2010-01-19

Similar Documents

Publication Publication Date Title
MXPA04004656A (es) Sintesis y purificacion de valaciclovir.
WO2005037825A3 (en) Protein kinase inhibitors
EP1423390A4 (en) PURIN INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
IL214440A (en) A method for improving the stability of in vitro purified alpha-glucosidase
CA2401229A1 (en) Aryl fused azapolycyclic compounds
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
AU3546601A (en) Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
DE60125026D1 (de) Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
HK1066215A1 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2003084936A3 (en) Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
SI0773943T1 (en) Compounds useful as antiproliferative agents and garft inhibitors
MXPA05009668A (es) Proceso libre de azida para preparar compuestos de 1,2-diamino.
WO2004048340A8 (en) Sinomenine and sinomenine compounds, synthesis and use
HRP20080107T3 (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
MY138826A (en) 2,7-substituted indoles
IL150061A0 (en) Purine derivatives
AU6460501A (en) Preparation of iminodiacetic acid compounds from monoethanolamine substrates
CA2310714A1 (en) Process for preparing neuraminidase inhibitor ro-64-0796
MXPA03001356A (es) Nuevos agentes inhibidores de beta-amiloides, procedimientos para su preparacion y su uso como medicamentos.
AU2001281250A1 (en) (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
TW200500369A (en) Cephem compounds
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs

Legal Events

Date Code Title Description
FG Grant or registration